These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 25201757)

  • 1. Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms.
    Prick J; de Haan G; Green AR; Kent DG
    Exp Hematol; 2014 Oct; 42(10):841-51. PubMed ID: 25201757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The JAK2 mutation.
    Merchant S
    Int Rev Cell Mol Biol; 2021; 365():117-162. PubMed ID: 34756242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal.
    Shepherd MS; Li J; Wilson NK; Oedekoven CA; Li J; Belmonte M; Fink J; Prick JCM; Pask DC; Hamilton TL; Loeffler D; Rao A; Schröder T; Göttgens B; Green AR; Kent DG
    Blood; 2018 Aug; 132(8):791-803. PubMed ID: 29991556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2 and MPL mutations in myeloproliferative neoplasms.
    Koppikar P; Levine RL
    Acta Haematol; 2008; 119(4):218-25. PubMed ID: 18566540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion.
    Kent DG; Li J; Tanna H; Fink J; Kirschner K; Pask DC; Silber Y; Hamilton TL; Sneade R; Simons BD; Green AR
    PLoS Biol; 2013; 11(6):e1001576. PubMed ID: 23750118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
    Dunbar A; Nazir A; Levine R
    Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
    Sun T; Zhang L
    Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
    Rampal R; Levine RL
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronic granulocytic leukemia as a proliferative panmyelopathy of a clonal nature].
    Sánchez Fayos J; Lasierra Cirujeda J
    Sangre (Barc); 1984; 29(4-B):491-501. PubMed ID: 6393378
    [No Abstract]   [Full Text] [Related]  

  • 10. Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms.
    Zhang J; Fleischman AG; Wodarz D; Komarova NL
    J Theor Biol; 2017 Jul; 425():43-52. PubMed ID: 28501635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis and clonal evolution of myeloproliferative neoplasms.
    Cleary C; Kralovics R
    Clin Chem Lab Med; 2013 Oct; 51(10):1889-96. PubMed ID: 23729579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2V617F mutant endothelial cells promote neoplastic hematopoiesis in a mixed vascular microenvironment.
    Mazzeo C; Quan M; Wong H; Castiglione M; Kaushansky K; Zhan H
    Blood Cells Mol Dis; 2021 Sep; 90():102585. PubMed ID: 34139651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloproliferative neoplasm stem cells.
    Mead AJ; Mullally A
    Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional interdependence of hematopoietic stem cells and their niche in oncogene promotion of myeloproliferative neoplasms: the 159th biomedical version of "it takes two to tango".
    Zhan H; Kaushansky K
    Exp Hematol; 2019 Feb; 70():24-30. PubMed ID: 30593829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathology of myeloproliferative neoplasms.
    Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
    Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.
    Zhang SJ; Abdel-Wahab O
    Curr Hematol Malig Rep; 2012 Mar; 7(1):34-42. PubMed ID: 22170482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].
    Chen YX; Li Y; Zhang LY; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1329-33. PubMed ID: 22040998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.
    James C; Mazurier F; Dupont S; Chaligne R; Lamrissi-Garcia I; Tulliez M; Lippert E; Mahon FX; Pasquet JM; Etienne G; Delhommeau F; Giraudier S; Vainchenker W; de Verneuil H
    Blood; 2008 Sep; 112(6):2429-38. PubMed ID: 18612101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.
    Zhao B; Mei Y; Cao L; Zhang J; Sumagin R; Yang J; Gao J; Schipma MJ; Wang Y; Thorsheim C; Zhao L; Stalker T; Stein B; Wen QJ; Crispino JD; Abrams CS; Ji P
    J Clin Invest; 2018 Jan; 128(1):125-140. PubMed ID: 29202466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.
    Mansier O; Kilani B; Guitart AV; Guy A; Gourdou-Latyszenok V; Marty C; Parrens M; Plo I; Vainchenker W; James C
    Blood; 2019 Dec; 134(26):2383-2387. PubMed ID: 31697834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.